Patents Issued in March 7, 2017
  • Patent number: 9586996
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: March 7, 2017
    Assignee: ESPERANCE PHARMACEUTICALS, INC.
    Inventors: Hector Alila, Carola Leuschner
  • Patent number: 9586997
    Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: March 7, 2017
    Assignees: BioNtech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
  • Patent number: 9586998
    Abstract: The invention provides methods for propagating a monkey adenovirus in a cell, including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus, including a replication-deficient monkey adenovirus, obtained by such propagation methods.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: March 7, 2017
    Assignee: GenVec, Inc.
    Inventors: Jason Gall, Douglas Brough, Christoph Kahl, Duncan McVey
  • Patent number: 9586999
    Abstract: Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 7, 2017
    Assignee: University of Utah Research Foundation
    Inventors: Grzegorz Bulaj, H. Steve White
  • Patent number: 9587000
    Abstract: The present application describes a cell that has integrated into its genome fusion molecule V16-CREB.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: March 7, 2017
    Inventor: Sung Ho Hahm
  • Patent number: 9587001
    Abstract: Disclosed are knottin peptides containing non-natural amino acids so that they can be formed by chemical conjugation into two or more knottin monomers. The knottin monomers comprise a non-natural amino acid such as an aminooxy residue within the polypeptide sequence. The exemplified dimers were produced by oxime formation between two aldehyde groups present on a polyether linker and an aminooxy functional group that was site-specifically incorporated the knottin. Knottins variants based on EETI (Ecballium elaterium trypsin inhibitor) and AgRP (Agouti-related protein) were engineered to contain integrin-binding loops. These dimers were shown to have increased binding strength to integrins on U87MG tumor cells, achieving significant increases in inhibition of cell adhesion and proliferation. Also disclosed are knottin monomers comprising an aminooxy residue; these may be conjugated to molecules such as doxorubicin.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: March 7, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Jun Woo Kim, Frank V. Cochran
  • Patent number: 9587002
    Abstract: This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed thereby, and pharmaceutical compositions that contain all these elements. These compositions may be used in the treatment of diseases from the following group: ageing or acceleration of ageing, neurodegenerative diseases and dyskeratosis congenita.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: March 7, 2017
    Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, UNIVERSIDAD AUTONOMA DE MADRID—FUNDACION GENERAL, UNIVERSIDAD POLITECNICA DE VALENCIA
    Inventors: Rosario Perona Abellon, Rosario Machado Pinilla, Leandro Sastre Garzon, Isabel Sanchez Perez, Jose Ramon Murguia Ibanez
  • Patent number: 9587003
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: March 7, 2017
    Assignee: ModernaTX, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Patent number: 9587004
    Abstract: This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: March 7, 2017
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Candace Y. W. Lee, John C. Burnett, Jr.
  • Patent number: 9587005
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: March 7, 2017
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Brian P. Ward
  • Patent number: 9587006
    Abstract: Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5? to 3? direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO: 01, b) expressing the nucleic acid of a) in a cell and recovering the expression construct from the cell and/or the cultivation medium, c) providing a target peptide with an amino acid sequence of SEQ ID NO: 02 covalently conjugated to a poly (ethylene glycol) at the C-terminal lysine residue, d) incubating the expression construct and the target peptide with the trypsin mutant D189K, K60E, N143H, E151H, and e) recovering and thereby producing the polypeptide conjugated to one poly (ethylene glycol) from the incubation mixture.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: March 7, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Friederike Hesse, Eva Hoess, Stephanie Mueller, Eva Maria Trost-Gross
  • Patent number: 9587007
    Abstract: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: March 7, 2017
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko Akamatsu, Veronica Juan, Robert B. Dubridge
  • Patent number: 9587008
    Abstract: Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: March 7, 2017
    Assignee: APTEVO BIOTHERAPEUTICS LLC
    Inventors: William N. Drohan, Michael J. Griffith
  • Patent number: 9587009
    Abstract: The invention relates generally to solid supports for chromatography. In specific embodiments the invention provides for solid supports suitable for affinity chromatography along with methods, systems and kits which use the same.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: March 7, 2017
    Assignee: EMD Millipore Corporation
    Inventors: Nanying Bian, Senthil Ramaswamy, Neil Soice, Chen Wang, Yuan Wong
  • Patent number: 9587010
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: March 7, 2017
    Assignee: THE INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventor: Antonio Lanzavecchia
  • Patent number: 9587011
    Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: March 7, 2017
    Assignee: Pomona Ricerca S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 9587012
    Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 7, 2017
    Assignee: AARON DIAMOND AIDS RESEARCH CENTER
    Inventors: David D. Ho, Yaoxing Huang, Jian Yu
  • Patent number: 9587013
    Abstract: The invention provides methods for isolating a modified peptide from a complex mixture of peptides, the method comprising the steps of: (a) obtaining a proteinaceous preparation from an organism, wherein the preparation comprises modified peptides from two or more different proteins; (b) contacting the preparation with at least one immobilized modification-specific antibody; and (c) isolating at least one modified peptide specifically bound by the immobilized modification-specific antibody in step (b). The method may further comprise the step of (d) characterizing the modified peptide isolated in step (c) by mass spectrometry (MS), tandem mass spectrometry (MS-MS), and/or MS3 analysis, or the step of (e) utilizing a search program to substantially match the spectra obtained for the modified peptide during the characterization of step (d) with the spectra for a known peptide sequence, thereby identifying the parent protein(s) of the modified peptide.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: March 7, 2017
    Assignee: Cell Signaling Technology, Inc.
    Inventors: John Rush, Hui Zhang, Xiangming Zha, Michael J Comb, Yi Tan
  • Patent number: 9587014
    Abstract: Provided are novel TAR DNA-binding proteins of 43 kDa (“TDP-43”)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: March 7, 2017
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Roger Nitsch, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
  • Patent number: 9587015
    Abstract: Novel anti-human CTGF antibodies having excellent binding activity and/or neutralizing activity, as compared with conventional anti-human CTGF antibodies, are useful for treating various diseases in which human CTGF is involved in pathogenesis, including renal diseases such as chronic kidney disease and diabetic nephropathy.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 7, 2017
    Assignee: Astellas Pharma Inc.
    Inventors: Shoji Iwasaki, Ryuichi Moriya, Masayasu Yoshino, Koji Takakura
  • Patent number: 9587016
    Abstract: The present invention relates to methods and medicaments useful for pre-treatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: March 7, 2017
    Assignee: FIBROGEN, INC.
    Inventor: Kenneth E. Lipson
  • Patent number: 9587018
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 7, 2017
    Inventors: Juan Carlos Almagro, William DuBell, Johann Fransson, Jose Pardinas, Gopalan Raghunathan
  • Patent number: 9587019
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: March 7, 2017
    Assignee: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • Patent number: 9587020
    Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: March 7, 2017
    Assignee: The Regents of the University of California
    Inventors: Chia-Yung Wu, James Onuffer, Wendell A. Lim
  • Patent number: 9587021
    Abstract: CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey) are presented. Uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions are presented.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: March 7, 2017
    Assignee: MacroGenics, Inc.
    Inventors: Ling Huang, Leslie S. Johnson
  • Patent number: 9587022
    Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: March 7, 2017
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Ruijiang Song, David D. Ho
  • Patent number: 9587023
    Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 7, 2017
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
  • Patent number: 9587024
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?v?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 7, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • Patent number: 9587025
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: March 7, 2017
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Patent number: 9587026
    Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: March 7, 2017
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, Jose Carlos Escobar, Arvia E. Morris
  • Patent number: 9587027
    Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: March 7, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Emma Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
  • Patent number: 9587028
    Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 7, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Brigham and Women's Hospital
    Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang, Thomas S. Kupper
  • Patent number: 9587029
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 7, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • Patent number: 9587030
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: March 7, 2017
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosma{hacek over (c)}
  • Patent number: 9587031
    Abstract: The present invention can provide a monoclonal antibody which comprises a heavy chain constant region which is IgG2 wherein valine at position 234, glutamine at position 237 and proline at position 331 are at least substituted with alanine, alanine and serine, respectively (numbering is based on the EU index of Kabat et al); has an agonist activity; and binds to human CD40.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: March 7, 2017
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Aki Matsushima, Hiroshi Namisaki, Shigenori Yagi
  • Patent number: 9587032
    Abstract: The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: March 7, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Joseph A. Mollick, Pearline Teo, Paul J. Utz
  • Patent number: 9587033
    Abstract: Disclosed herein are novel antibodies specific to Tnk1 or variants thereof. Also disclosed are methods of using such antibodies. The methods include therapeutic methods against certain types of cancers or infections involving administration of novel antibodies or fragments thereof. Also, methods of using highly selective antibodies for detecting aberrant Tnk1 or functionally deficient Tnk1.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: March 7, 2017
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Hoare Kishalay, William Stratford May, Sarasija Hoare
  • Patent number: 9587034
    Abstract: Antibodies binding to junction regions between the CH4 and C?mX domains of membrane-bound IgE and uses thereof in treating IgE-mediated diseases such as allergic diseases.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 7, 2017
    Assignee: Academia Sinica
    Inventors: Tse Wen Chang, Jiun-Bo Chen, Chien-Jen Lin, Nien-Yi Chen
  • Patent number: 9587035
    Abstract: The invention relates to the detection and quantification of 1-benzylpiperazine and its metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: March 7, 2017
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
  • Patent number: 9587036
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: March 7, 2017
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter Kufer, Ralf Lutterbuese, Matthias Klinger, Petra Fluhr, Doris Rau, Susanne Hausmann, Carola Steiger, Tobias Raum, Patrick Hoffmann, Roman Kischel, Evelyne Schaller, Susanne Mangold
  • Patent number: 9587037
    Abstract: A process for recovering an esterified cellulose ether from a reaction product mixture obtained from a reaction of (a) a cellulose ether with (b) an aliphatic monocarboxylic acid anhydride or a di- or tricarboxylic acid anhydride or a combination of an aliphatic monocarboxylic acid anhydride and a di- or tricarboxylic acid anhydride, comprises the steps of (i) contacting the reaction product mixture with an aqueous liquid to precipitate the esterified cellulose ether from the reaction product mixture, (ii) isolating the precipitated esterified cellulose ether from the mixture obtained in step (i), and (iii) suspending the isolated esterified cellulose ether in an aqueous liquid to provide a suspension having a temperature of at least 28° C., and (iv) recovering the esterified cellulose ether from the suspension of step (iii).
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: March 7, 2017
    Inventors: Oliver Petermann, Matthias Sprehe, Robert Appell, Robert Nilsson
  • Patent number: 9587038
    Abstract: The present invention relates to a process for producing microcellulose comprising a) acidifying fibrous cellulosic material, b) washing the acidified cellulosic material, c) optionally dewatering the washed cellulosic material, and d) hydrolyzing the washed or washed and dewatered cellulosic material under acidic conditions at a temperature of at least 120° C. and at a consistency of at least 8% on dry weight of the cellulose.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: March 7, 2017
    Assignee: Kemira Oyj
    Inventors: Erkki Iikka Sakari Rasanen, Leif Robertsen, Veli-Matti Vuorenpalo, Asko Karppi, Kari Parviainen, Olli Dahl, Kari Vanhatalo
  • Patent number: 9587039
    Abstract: Provided is a fluorine-containing macroinitiator, particularly a fluorine-containing macroinitiator that enables production of a fluorine-containing block copolymer containing a non-fluorine vinyl-based monomer having a long side chain. The fluorine-containing macroinitiator includes a polymer represented by the following formula (1) and having a number-average molecular weight of 3,000 to 100,000. In the following formula (1), R2, R3 and R4 are each a specific group, and Q is a polymer segment composed of a structural unit represented by the following formula (2). In the following formula (2), R1 is a hydrogen atom or a methyl group, Rf is a fluoroalkyl group having a specific structure, and k is an appropriate integer that is not 0.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: March 7, 2017
    Assignee: Unimatec Co., Ltd.
    Inventors: Satoru Saito, Katsuyuki Sato, Takehiro Sonoi
  • Patent number: 9587040
    Abstract: Process for the preparation of solid particles of a magnesium-chloride alcohol adduct comprising (a) forming an emulsion between a MgCl2 .alcohol adduct in molten form and a liquid phase which is immiscible with the said adduct in the presence of a polyalkyl-methacrylate used as a solution having viscosity ranging from 100 to 5000 mm2/s and (b) rapidly cooling the emulsion to solidify the disperse phase and collecting the solid adduct particles.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: March 7, 2017
    Assignee: Basell Poliolefine Italia S.r.l.
    Inventors: Benedetta Gaddi, Daniele Evangelisti, Gianni Collina
  • Patent number: 9587041
    Abstract: The present invention provides a solid organomagnesium precursor having formula {Mg(OR?)X}.a{MgX2}.b{Mg(OR?)2}.c{R?OH}, wherein R? is selected from a hydrocarbon group, X is selected from a halide group, and a:b:c is in range of 0.01-0.5:0.01-0.5:0.01-5 and process for preparing the same, said process comprising contacting a magnesium source with a solvating agent, an organohalide and an alcohol to obtain the solid organomagnesium precursor. The present invention also provides a process for preparing a catalyst system using the organomagnesium precursor and its use thereof for polymerization of olefins. The organomagnesium precursor is prepared as follows: At 0° C., magnesium in diethyl ether is reacted with the organohalide. After all magnesium has reacted, the calculated amount of alcohol was added and after the completion of addition, the ether was evaporated and a solid compound obtained.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: March 7, 2017
    Assignee: INDIAN OIL CORPORATION LIMITED
    Inventors: Sukhdeep Kaur, Gurmeet Singh, Bhasker Bantu, Naresh Kumar, Gurpreet Singh Kapur, Shashi Kant, Biswajit Basu, Ravinder Kumar Malhotra
  • Patent number: 9587042
    Abstract: An object of the present invention is to provide a process for producing a modified conjugated diene-based polymer suitable for preparing a polymer composition excellent in the fuel cost saving effect. The present invention provides a process for producing a modified conjugated diene-based polymer, comprising reacting a conjugated diene-based polymer having a monomer unit based on a conjugated diene compound and a monomer unit based on a compound represented by the following formula (1), with an organometallic compound, and reacting the resulting reaction product with a hydrocarbyloxysilane compound: wherein R11, R12, R13, R14 and R15 each represent a hydrogen atom or an alkyl group, at least one of R11, R12, R13, R14 and R15 is an alkyl group, R16, R17 and R18 each represent a hydrogen atom or a hydrocarbyl group, R19 represents a hydrocarbylene group, and k represents 0 or 1.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: March 7, 2017
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Mana Ito
  • Patent number: 9587043
    Abstract: A crosslinkable and crosslinked polymer composition with improved DC electrical properties and a cable surrounded by at least one layer comprising the polymer composition are provided.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: March 7, 2017
    Assignee: BOREALIS AG
    Inventors: Ulf Nilsson, Annika Smedberg, Alfred Campus
  • Patent number: 9587044
    Abstract: Polypropylene having a melt flow rate MFR2 (230° C.) of at least 20 g/10 min; and a Mw/Mn ratio of at least 15.0.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: March 7, 2017
    Assignee: Borealis AG
    Inventors: Norbert Hafner, Klaus Bernreitner, Marcus Gahleitner
  • Patent number: 9587045
    Abstract: The present invention relates to the use of polyamidohydroxamates in washing and cleaning agents to improve cleaning performance, in particular with regard to stains containing polymerizable dyes.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: March 7, 2017
    Assignee: Henkel AG & Co. KGaA
    Inventors: Christian Kropf, Benoit Luneau, Siglinde Erpenbach, Andre Hatzelt, Thomas Weber
  • Patent number: 9587046
    Abstract: Disclosed are a photocurable composition which includes (A) a photocurable monomer and (B) a monomer represented by Formula 1, and an apparatus including a protective layers formed of the composition;
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: March 7, 2017
    Assignee: CHEIL INDUSTRIES, INC.
    Inventors: Chang Min Lee, Seung Jib Choi, Ji Hye Kwon, Kyoung Jin Ha, Yeon Soo Lee